查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884041

白喉、破伤风和百日咳 (DTP) 疫苗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测 (2024-2032)

Diphtheria, Tetanus, and Pertussis (DTP) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 请询问到货日

价格

白喉、破伤风和百日咳 (DTP) 疫苗市场成长驱动因子

由于传染病病例的增加、疫苗接种计划的加强以及疫苗技术的进步，全球白喉、破伤风和百日咳 (DTP) 疫苗市场持续稳步增长。报告显示，该市场预计将在 2024 年达到 102.3 亿美元，到 2025 年将增长至 116.9 亿美元，并在 2032 年迅速达到 333.8 亿美元。这反映了随着各国政府和国际卫生组织提高疫苗接种覆盖率，该市场强劲的成长动能。 DTP疫苗对于预防危及生命的细菌感染至关重要，其在儿童和成人免疫接种计画中的市场需求持续成长。

市场概览

DTP疫苗可预防婴幼儿常见的三种严重细菌感染：白喉、破伤风和百日咳。多种配方，包括DTaP、Tdap、DT/Td和联合疫苗，可涵盖广泛的年龄层。疾病发生率的上升是推动疫苗普及的关键因素。世界卫生组织（世卫组织）报告称，2022年全球百日咳病例将超过62,500例，其中仅西太平洋地区就有39,000例，凸显了百日咳的持续威胁。如此高的感染率有力地证明了进行常规儿童免疫接种和加强免疫接种计划的必要性。

此外，葛兰素史克（GSK plc）、赛诺菲（Sanofi）、默克（Merck & Co.）、印度血清研究所（Serum Institute of India）、Biological E Limited 和 BioNet Asia 等主要製药公司正透过持续供应、创新和全球分销能力来巩固市场地位。

市场成长驱动因素

疫苗可预防疾病负担沉重

呼吸道细菌感染发生率的上升是推动市场成长的最重要因素之一。根据美国疾病管制与预防中心（CDC）发布的 2024 年中期报告，2024 年将确诊 35,435 例百日咳病例，其中超过 6,500 例为 1 至 6 岁儿童。这凸显了主动接种疫苗的迫切性，尤其是在儿童群体中。

扩大免疫接种计画

世界各国政府正在进行宣传活动，以确保及时接种疫苗。例如，2025年4月，中国在全国儿童免疫日之际，开展了一项全国性的宣传活动，向家庭普及百日咳的风险和接种疫苗的好处。

同样，全球疫苗免疫联盟（GAVI）在2023年更新的疫苗接种计划中，在符合条件的国家引入了百白破加强剂和六价疫苗，从而扩大了疫苗接种覆盖范围。

市场限制

疫苗犹豫与认知不足

在低收入地区，宗教误解、安全疑虑和教育不足阻碍了疫苗的广泛接种。在吉尔吉斯斯坦，截至2024年底，仍有超过22,000名儿童因拒绝接种疫苗或受到错误讯息误导而未接种疫苗，这表明疫苗接种工作仍面临持续挑战。

冷链限制

对温度敏感的百白破疫苗需要持续储存在2°C至8°C的温度下。根据印度国家疫苗浪费评估报告，13.5%的百白破疫苗因冷链故障而被浪费，直接影响了疫苗供应的可靠性。

市场机会

政府支持并扩大资金投入

各国政府正大力投资全国疫苗接种运动。例如，印度2025年针对学龄儿童的破伤风白喉疫苗接种运动提高了加强剂的接种覆盖率。同样，巴西和圭亚那将于2025年举办“跨国免疫週”，为弱势群体接种疫苗。

转换成重组技术

现代基因工程方法正在提高免疫原性和保护持续时间。 BioNet Asia 的重组百日咳疫苗已于 2024 年提交给欧洲药品管理局 (EMA)，这标誌着疫苗研发正朝着更安全、更有效的方向发展，并为新的市场成长铺平道路。

细分市场概览

依技术分类

  • 由于灭活疫苗的广泛应用以及世界卫生组织报告的 2023 年婴儿 DTP-3 疫苗接种率达到 84%，因此灭活疫苗将在 2024 年占主导地位。
  • 随着各公司开发出更安全、免疫原性更强的配方，预计从 2025 年到 2032 年，重组技术将变得更加普及。

按类型

  • 由于DTaP疫苗在婴幼儿免疫接种中的作用，其在2024年占市场主导地位。
  • Tdap疫苗在较大儿童、成人和孕妇中的使用量持续稳定成长。

依年龄组

  • 由于感染率高和强制性疫苗接种计划，儿科在2024年占市场主导地位。
  • 由于每10年进行一次加强免疫接种，成人需求保持稳定。

按分销管道

  • 由于国家免疫计划，政府供应链占最大占有率。
  • 随着疫苗接种管道的扩大，医院和零售药局的市占率也在成长。

区域概览

北美

预计2024年，北美市场规模将达到58.6亿美元，凭藉高疾病通报率、先进的医疗保健系统和强大的供应链，引领全球市场。预计到2024年，美国百日咳病例数将激增至11,568例，将推动疫苗需求。

亚太地区

预计到2032年，经济高效的疫苗、庞大的人口规模以及政府主导的疫苗接种运动将推动亚太地区市场以最高的复合年增长率成长。

欧洲

得益于获得世卫组织认证的监管设施（例如，德国将于2024年被指定为世卫组织白喉合作中心），保持着较高的市场占有率。

拉丁美洲、中东和非洲

透过跨国努力和农村疫苗接种活动，疫苗接种率正在缓慢但稳定地提高。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 各国主要疾病流行情形（2024 年）
  • 主要产业趋势（新产品发表、併购、合作等）
  • 主要公司产品线分析
  • 各国白喉-破伤风-百日咳 (DTP) 疫苗接种率概述

章节5：全球白喉-破伤风-百日咳 (DTP) 疫苗市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 按技术分类
    • 灭活​​疫苗
    • 其他
  • 市场分析、洞察与预测 - 按类型分类
    • DTaP 疫苗
    • Tdap 疫苗
    • DT/Td 疫苗
    • 其他
  • 市场分析、洞察与预测 - 按年龄组分类
    • 儿童疫苗
    • 成人疫苗
  • 市场分析、洞察与预测 - 按分销管道分类
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美白喉-破伤风-百日咳 (DTP) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲白喉、破伤风和百日咳 (DTP) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家/地区
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区白喉、破伤风和百日咳 (DTP) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲白喉、破伤风和百日咳 (DTP) 疫苗市场分析、洞察和预测 (2019-2032)

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲白喉-破伤风-百日咳 (DTP) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
  • 葛兰素史克 (GSK plc)
  • 赛诺菲 (Sanofi)
  • 默克公司 (Merck & Co., Inc.)
  • 宝灵生物製药株式会社 (Boryung Biopharma Co.)
  • 印度血清研究所 (Serum Institute of India Pvt.)有限公司
  • 武汉生物製品研究所有限公司
  • BioNet-Asia
  • Bio Farma
  • Biological E Limited
Product Code: FBI113648

Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is experiencing robust expansion driven by rising infectious disease cases, strengthened immunization programs, and advancements in vaccine technologies. According to the report, the market reached USD 10.23 billion in 2024, is expected to grow to USD 11.69 billion by 2025, and is projected to surge to USD 33.38 billion by 2032, reflecting a strong trajectory as governments and global health organizations increase vaccination coverage. With DTP vaccines essential for preventing life-threatening bacterial infections, the market continues to gain momentum across pediatric and adult immunization programs.

Market Overview

DTP vaccines protect against three severe bacterial infections-diphtheria, tetanus, and pertussis-commonly affecting infants and young children. Multiple formulations such as DTaP, Tdap, DT/Td, and combination vaccines ensure broad applicability across age groups. Rising disease incidence is a critical factor driving adoption. The WHO reported over 62,500 global pertussis cases in 2022, with 39,000 in the Western Pacific region alone, highlighting the continued threat of whooping cough. These high infection rates reinforce the need for routine childhood immunization and booster programs.

Furthermore, leading pharmaceutical companies such as GSK plc, Sanofi, Merck & Co., Serum Institute of India, Biological E Limited, and BioNet-Asia strengthen the market with continuous supply, innovation, and global distribution capabilities.

Market Growth Drivers

High Burden of Vaccine-Preventable Diseases

Growing cases of respiratory bacterial infections are one of the most significant market drivers. CDC's Provisional 2024 Report revealed 35,435 pertussis cases in 2024, with over 6,500 cases in children aged 1-6 years. This has increased the urgency for active immunization, particularly among pediatric populations.

Expanding Vaccination Programs

Governments worldwide are initiating awareness campaigns to ensure timely vaccinations. For example, in April 2025, China launched a nationwide campaign during National Children's Vaccination Day to educate families on pertussis risks and the benefits of immunization.

Similarly, GAVI's 2023 update introduced DTP booster doses and hexavalent vaccines in eligible countries, enabling broader coverage.

Market Restraints

Vaccine Hesitancy & Lack of Awareness

In low-income regions, religious misconceptions, safety concerns, and limited education restrict vaccination uptake. In the Kyrgyz Republic, more than 22,000 children remained unvaccinated by end-2024 due to refusals and misinformation, demonstrating persistent challenges.

Cold Chain Limitations

Temperature-sensitive DTP vaccines require continuous storage between 2°C-8°C. According to India's National Vaccine Wastage Assessment, 13.5% of DPT vaccines were wasted due to cold-chain failures, directly affecting supply reliability.

Market Opportunities

Growing Government Support & Funding

Governments are investing heavily in nationwide vaccination drives. For instance, India's 2025 Td Vaccination Campaign for schoolchildren enhanced booster dose coverage. Similarly, Brazil and Guyana's Cross-Border Vaccination Week (2025) aims to immunize vulnerable populations.

Shift Toward Recombinant Technologies

Modern genetic engineering methods improve immunogenicity and duration of protection. BioNet-Asia's 2024 submission to EMA for its recombinant pertussis vaccine marks a shift toward safer, more effective vaccines, fueling new market growth avenues.

Segmentation Overview

By Technology

  • Inactivated vaccines dominated 2024, driven by widespread use and WHO-reported 84% infant DTP-3 coverage in 2023.
  • Recombinant technologies are expected to gain traction from 2025-2032 as companies develop safer, more immunogenic formulations.

By Type

  • DTaP vaccines led 2024 due to their role in infant immunization.
  • Tdap vaccines continue to expand moderately for older children, adults, and pregnant women.

By Age Group

  • Pediatrics dominated the market in 2024 due to high infection rates and mandatory immunization schedules.
  • Adults maintain steady demand through booster doses every 10 years.

By Distribution Channel

  • Government suppliers held the largest share due to national immunization programs.
  • Hospital and retail pharmacies are growing as access to vaccinations expands.

Regional Insights

North America

Generated USD 5.86 billion in 2024, leading globally due to high disease reporting, advanced health systems, and strong supply chains. U.S. pertussis cases surged to 11,568 in 2024, increasing vaccination demand.

Asia Pacific

Expected to grow at the highest CAGR through 2032, driven by cost-effective vaccines, large population, and government immunization drives.

Europe

Maintains strong share with WHO-recognized regulatory facilities, such as Germany's 2024 designation of a WHO Collaborating Center for Diphtheria.

Latin America & Middle East/Africa

Show moderate but rising adoption through cross-border and rural immunization initiatives.

Conclusion

With market value rising from USD 10.23 billion (2024) to USD 33.38 billion (2032), the global DTP vaccines market is poised for strong long-term expansion. Increasing disease prevalence, large-scale immunization campaigns, and advancements in recombinant technology will continue to strengthen global vaccine coverage and market growth.

Segmentation By Technology

  • Inactivated
  • Others

By Type

  • DTaP Vaccine
  • Tdap Vaccine
  • DT/ Td vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries, 2024
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries

5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Inactivated
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. DTaP Vaccine
    • 5.2.2. Tdap Vaccine
    • 5.2.3. DT/ Td vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Inactivated
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. DTaP Vaccine
    • 6.2.2. Tdap Vaccine
    • 6.2.3. DT/ Td vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Inactivated
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. DTaP Vaccine
    • 7.2.2. Tdap Vaccine
    • 7.2.3. DT/ Td vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Inactivated
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. DTaP Vaccine
    • 8.2.2. Tdap Vaccine
    • 8.2.3. DT/ Td vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Inactivated
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. DTaP Vaccine
    • 9.2.2. Tdap Vaccine
    • 9.2.3. DT/ Td vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Inactivated
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. DTaP Vaccine
    • 10.2.2. Tdap Vaccine
    • 10.2.3. DT/ Td vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Boryung Biopharma Co.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Serum Institute of India Pvt. Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BioNet-Asia.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Biological E Limited.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2033
  • Table 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 12: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 13: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 14: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 16: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 17: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 19: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 21: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 22: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 23: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 24: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 26: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 27: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 28: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 29: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032

List of Figures

  • Figure 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024 & 2032
  • Figure 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group 2024 & 2032
  • Figure 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 11: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 12: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 13: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 18: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 19: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 20: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 21: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 22: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 23: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 26: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 27: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 28: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 29: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 30: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 31: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 32: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 33: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 36: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 37: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 38: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 39: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 40: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 41: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 42: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 43: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 46: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 47: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 48: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 49: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 50: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 51: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 52: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 53: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 56: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 57: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Share (%), By Company, 2024